{"altmetric_id":4687979,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Amgen"],"first_seen_on":"2015-10-28T12:39:56+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1431722340,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01952574?show_locs=Y"],"nct_id":"NCT01952574","pubdate":"2013-08-30T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"A Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention","type":"clinical_trial_study_record"},"altmetric_score":{"score":5.256,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":5.256},"context_for_score":{"all":{"total_number_of_other_articles":5099132,"mean":6.0427967663529,"rank":900599,"this_scored_higher_than_pct":82,"this_scored_higher_than":4197903,"rank_type":"exact","sample_size":5099132,"percentile":82},"similar_age_3m":{"total_number_of_other_articles":192310,"mean":10.13528090729,"rank":44019,"this_scored_higher_than_pct":77,"this_scored_higher_than":148286,"rank_type":"exact","sample_size":192310,"percentile":77},"this_journal":{"total_number_of_other_articles":13419,"mean":5.5362164256968,"rank":3148,"this_scored_higher_than_pct":76,"this_scored_higher_than":10241,"rank_type":"exact","sample_size":13419,"percentile":76},"similar_age_this_journal_3m":{"total_number_of_other_articles":708,"mean":8.7727637906648,"rank":168,"this_scored_higher_than_pct":75,"this_scored_higher_than":538,"rank_type":"exact","sample_size":708,"percentile":75}}},"demographics":[],"counts":{"total":{"posts_count":1},"blogs":{"unique_users_count":1,"unique_users":[55704],"posts_count":1}},"posts":{"blogs":[{"title":"Trial Shows Antibody Reduces Days with Migraines","url":"http:\/\/sciencebusiness.technewslit.com\/?p=26998","license":"public","citation_ids":[4687979,2222745],"posted_on":"2015-05-15T20:39:00+00:00","summary":"(R. Nial Bradshaw, Flickr)\n15 May 2015. A clinical trial shows high doses of an engineered antibody reduced the number of days per month that people with a history of migraines experience migraine episodes. First findings from the intermediate-stage trial","author":{"name":"Science and Enterprise","url":"http:\/\/sciencebusiness.technewslit.com","description":"Science for business people. Enterprise for scientists."}}]}}